Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Generated: May 27, 2017

DrugPatentWatch Database Preview

Mepivacaine hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for mepivacaine hydrochloride and what is the scope of mepivacaine hydrochloride patent protection?

Mepivacaine hydrochloride
is the generic ingredient in seven branded drugs marketed by Hospira Inc, Fresenius Kabi Usa, Intl Medication Sys, Eastman Kodak, Novocol, Hospira, Dentsply Pharm, Belmora Llc, Watson Labs, Solvay, and Deproco, and is included in sixteen NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

There are six drug master file entries for mepivacaine hydrochloride. Thirteen suppliers are listed for this compound.

Summary for Generic Name: mepivacaine hydrochloride

Drug Master File Entries: see list6
Suppliers / Packagers: see list13
Bulk Api Vendors: see list59
Clinical Trials: see list1,007
Patent Applications: see list754
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:mepivacaine hydrochloride at DailyMed

Pharmacology for Ingredient: mepivacaine hydrochloride

Drug ClassAmide Local Anesthetic
Physiological EffectLocal Anesthesia
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Watson Labs
mepivacaine hydrochloride
INJECTABLE;INJECTION088770-001Nov 20, 1984DISCNNoNo► Subscribe► Subscribe
Fresenius Kabi Usa
mepivacaine hydrochloride
INJECTABLE;INJECTION089407-001Dec 1, 1986APRXNoNo► Subscribe► Subscribe
mepivacaine hydrochloride
INJECTABLE;INJECTION080925-001Approved Prior to Jan 1, 1982APRXNoYes► Subscribe► Subscribe
Fresenius Kabi Usa
mepivacaine hydrochloride
INJECTABLE;INJECTION089410-001Dec 1, 1986APRXNoNo► Subscribe► Subscribe
mepivacaine hydrochloride
INJECTABLE;INJECTION012250-002Approved Prior to Jan 1, 1982APRXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Set up watchlists for daily email updates

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus